Scientists Unveil Blueprint for Engineering Killer T Cells to Target Cancer Cells
Scientists have made a groundbreaking discovery in the field of cancer research, revealing new genetic principles that govern how CD8 killer T cells decide their fate: to become long-lasting, protective warriors or to succumb to exhaustion and dysfunction. This finding opens up exciting possibilities for enhancing the therapeutic potential of these immune cells.
In a related development, researchers at UT Southwestern Medical Center have found a way to boost the stem-like behavior of engineered cancer-fighting immune cells by increasing the levels of a protein called BACH2. This discovery paves the way for novel strategies to enhance the efficacy of chimeric antigen receptor T cells, a promising approach in cancer immunotherapy.
Furthermore, a recent study has uncovered a previously unknown mechanism that explains why androgens persist in prostate cancer even after androgen deprivation therapy. This finding provides valuable insights into the progression of prostate cancer and may lead to new treatment approaches.
The European Commission has approved Breyanzi (lisocabtagene maraleucel), a groundbreaking CD19-directed chimeric antigen receptor T cell therapy, for treating adult patients with relapsed or refractory mantle cell lymphoma who have received at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor. This approval marks a significant advancement in the treatment of mantle cell lymphoma.
Additionally, the National Cancer Institute (NCI) has awarded a substantial five-year grant of $11.2 million to Victoria Bae-Jump and Hazel Nichols at the University of North Carolina Lineberger Comprehensive Cancer Center. This funding will support their research on cancer health disparities, specifically focusing on endometrial cancer. The grant will enable them to explore innovative approaches to address the disparities in cancer outcomes among different populations.
In another significant development, researchers from the USC Norris Comprehensive Cancer Center at Keck School of Medicine of USC have demonstrated the safety and effectiveness of next-generation CAR T cells in reducing solid tumors. Their work, conducted using cell cultures and animal models, highlights the potential of these advanced immune cells in cancer treatment.
Reflecting on his early career, a renowned scientist at City of Hope shared his journey, recalling how he joined the institution’s pioneering bone marrow transplant (BMT) program, which aimed to improve outcomes for patients with advanced leukemia. This personal account underscores the dedication and innovation that drive progress in cancer research and treatment.
